drugset / Trial / NCT01174199

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

NCT01174199

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of temsirolimus and vorinostat in treating patients with metastatic prostate cancer.

Timeline

Start
2012-02
Primary completion
2015-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule Intravenous
Subject Vorinostat Small molecule Oral